Shannon N. Radomski

Shannon N. Radomski

Auto-generated profile, based on publicly available information

Shannon N. Radomski

Colorectal Research Unit, Department of Surgery The Johns Hopkins University School of Medicine Baltimore Maryland USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 October 2017 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
SRShannon Radomski
Shannon Radomski
SDSarah Marie Dermody
Sarah Marie Dermody
EHEarl H. Harley
Earl H. Harley

15 February 2023 in Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
HKHamza Khan
Hamza Khan
SRShannon N. Radomski
Shannon N. Radomski
ASAmn Siddiqi
Amn Siddiqi
NZNancy Zhou
Nancy Zhou
DPDane C. Paneitz
Dane C. Paneitz
JGJonathan B. Greer
Jonathan B. Greer
Background and Objectives: Tumor deposit (TD) is a poor prognostic factor in colorectal cancer (CRC) patients. This study aimed to determine whether TD carry the same risk of peritoneal recurrence as known high‐risk (HR) features in CRC patients.Methods: A retrospective cohort‐study of stage I−III CRC patients from 2010 to 2015 was conducted. TD group was defined by the presence of TD on histopathology whereas HR group was defined by the presence of obstruction, perforation, or T4‐stage.Results: A total of 151 patients with CRC were identified, of which 50 had TD and 101 had a HR feature. The overall risk of peritoneal recurrence was higher in the TD group versus HR group (36.0% vs. 19.8%, p = 0.03). The risk of peritoneum as the site of first recurrence was also higher in the TD group (22.0% vs. 12.9%, p = 0.03). Overall cancer recurrence at any site was also higher in the TD group (56.0% vs. 34.7%, p = 0.01). Median time to first recurrence was 1.2 (0.7−1.9) years in the TD group compared to 1.4 (0.8−2.1) years in the HR group (p = 0.31).Conclusions: In non‐metastatic CRC patients, TD might have a higher risk of tumor recurrence versus their HR counterparts. Alternative strategies for surveillance and treatment should be considered.

15 January 2019 in Laryngoscope Investigative Otolaryngology
Verified
Journal Article
Open access
PDF file
EMElaine Martin
Elaine Martin
SRShannon Radomski
Shannon Radomski
EHEarl Harley
Earl Harley
Objective: To determine the demographics, treatment modalities, and overall survival of patients with sinonasal sarcoma.Methods: All cases of primary sinonasal sarcomas diagnosed between the years of 2009 and 2014 were extracted from the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Additional variables collected included age, gender, ethnicity, tumor histological subtype, tumor size, treatment modality, vitality status, and follow‐up time. Kaplan‐Meier survival curves were generated and overall survival was calculated.Results: One hundred and four cases of sinonasal sarcoma were identified. The majority of patients were female (55%), white (76%), and non‐Hispanic (84%), and the mean age was 47 ± 22 years. The most common tumor sites were the maxillary sinus, followed by the ethmoid, sphenoid, and frontal sinus. Forty six percent of tumors were rhabdomyosarcoma type. Most patients (66%) had some type of surgery, 64% received radiation, and 58% received chemotherapy as part of their treatment. Overall 1‐ and 5‐year survival was 79% and 31%, respectively. There was no significant difference in survival based on patient gender, age, ethnicity, radiation, or chemotherapy treatment.Conclusions: This study adds to the current literature of sinonasal sarcomas and is the first to report in detail the surgical interventions performed as well as characteristics about lymph node spread, tumor histology, and treatment outcomes since the advent of radiation and chemotherapy. As these tumors are so rare, continued study of the demographics, tumor characteristics, and long‐term outcomes of this population is necessary to guide treatment modalities and strategies for otolaryngologists.Level of Evidence: 2b

13 July 2023 in Journal of Surgical Oncology
Verified
Journal Article
Closed access
SRShannon N. Radomski
Shannon N. Radomski
SCSophia Y. Chen
Sophia Y. Chen
MSMiloslawa Stem
Miloslawa Stem
JDJoy Z. Done
Joy Z. Done
JEJonathan E. Efron
Jonathan E. Efron
CAChady Atallah
Chady Atallah

16 March 2024 in Surgery
Verified
Journal Article
Open access
NWNolan M. Winicki
Nolan M. Winicki
SRShannon N. Radomski
Shannon N. Radomski
YCYusuf Ciftci
Yusuf Ciftci
ASAhmed H. Sabit
Ahmed H. Sabit
Fabian M. JohnstonFabian M. Johnston
Fabian M. Johnston
JGJonathan B. Greer
Jonathan B. Greer
Accurately predicting survival in patients with cancer is crucial for both clinical decision-making and patient counseling. The primary aim of this study was to generate the first machine-learning algorithm to predict the risk of mortality following the diagnosis of an appendiceal neoplasm. Patients with primary appendiceal cancer in the Surveillance, Epidemiology, and End Results database from 2000 to 2019 were included. Patient demographics, tumor characteristics, and survival data were extracted from the Surveillance, Epidemiology, and End Results database. Extreme gradient boost, random forest, neural network, and logistic regression machine learning models were employed to predict 1-, 5-, and 10-year mortality. After algorithm validation, the best-performance model was used to develop a patient-specific web-based risk prediction model. A total of 16,579 patients were included in the study, with 13,262 in the training group (80%) and 3,317 in the validation group (20%). Extreme gradient boost exhibited the highest prediction accuracy for 1-, 5-, and 10-year mortality, with the 10-year model exhibiting the maximum area under the curve (0.909 [±0.006]) after 10-fold cross-validation. Variables that significantly influenced the predictive ability of the model were disease grade, malignant carcinoid histology, incidence of positive regional lymph nodes, number of nodes harvested, and presence of distant disease. Here, we report the development and validation of a novel prognostic prediction model for patients with appendiceal neoplasms of numerous histologic subtypes that incorporate a vast array of patient, surgical, and pathologic variables. By using machine learning, we achieved an excellent predictive accuracy that was superior to that of previous nomograms.

25 June 2025 in Cancer
Verified
Journal Article
Closed access
SBSamuel D. Butensky
Samuel D. Butensky
VBVarun Bansal
Varun Bansal
DSDavid G Su
David G Su
MWMuhammad Talha Waheed
Muhammad Talha Waheed
ANAndrei Nikiforchin
Andrei Nikiforchin
PGPeritoneal Surface Malignancies Consortium Group
Peritoneal Surface Malignancies Consortium Group